Subclinical Hypothyroidism

  • Bernadette BiondiEmail author
  • Leonidas H. Duntas


This review summarizes the current knowledge regarding subclinical hypothyroidism, with special focus on etiology and the challenges in establishing the diagnosis and selection of those patients who will benefit from treatment. The disease is stratified into mild, moderate, and severe, thus type of therapy should be decided taking into consideration the stage of the disease together with the patient’s gender, comorbidities, and age. While most younger patients will benefit from treatment, among the elderly treatment decisions need to be based on a personalized approach.


Subclinical hypothyroidism Thyrotropin Thyroxine 


  1. 1.
    Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid. 2012;22:1200–35.CrossRefGoogle Scholar
  2. 2.
    Duntas LH. Subclinical hypothyroidism: a misnomer in search of a new name. Thyroid. 2001;11:361–2.CrossRefGoogle Scholar
  3. 3.
    Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of hypothyroidism. Br Med J. 1973;17(5854):657–62.CrossRefGoogle Scholar
  4. 4.
    Baumgartner C, Blum MR, Rodondi N. Subclinical hypothyroidism: summary of evidence in 2014. Swiss Med Wkly. 2014;144:w14058. Scholar
  5. 5.
    Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F, et al. The spectrum of thyroid disease in a community: the Wickham survey. Clin Endocrinol (Oxf). 1997;7:481–93.CrossRefGoogle Scholar
  6. 6.
    Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. The Colorado thyroid disease prevalence study. Arch Intern Med. 2000;160:526–34.CrossRefGoogle Scholar
  7. 7.
    Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D, Clark F, et al. The incidence of thyroid disorders in the community: a 20-year follow-up of the Wickham survey. Clin Endocrinol (Oxf). 1995;43:55–68.CrossRefGoogle Scholar
  8. 8.
    Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, et al. Subclinical thyroid disease—scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–38.CrossRefGoogle Scholar
  9. 9.
    Diez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J Clin Endocrinol Metab. 2004;89:4890–7.CrossRefGoogle Scholar
  10. 10.
    Somwaru LL, Rariy CM, Arnold AM, Cappola AR. The natural history of subclinical hypothyroidism in the elderly: the cardiovascular health study. J Clin Endocrinol Metab. 2012;97:1962–9.CrossRefGoogle Scholar
  11. 11.
    Andersen S, Pedersen KM, Bruun NH, Laurberg P. Narrow individual variations. in serum T(4) and T(3) in normal subjects: a clue to the understanding of subclinical thyroid disease. J Clin Endocrinol Metab. 2002;87:1068–72.CrossRefGoogle Scholar
  12. 12.
    Peeters RP. Subclinical hypothyroidism. N Engl J Med. 2017;376:2556–65.CrossRefGoogle Scholar
  13. 13.
    Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab. 2007;92:4575–82.CrossRefGoogle Scholar
  14. 14.
    Sichieri R, Baima J, Marante T, de Vasconcellos MT, Moura AS, Vaisman M. Low prevalence of hypothyroidism among black and mulatto people in a population-based study of Brazilian women. Clin Endocrinol (Oxf). 2007;66:803–70.CrossRefGoogle Scholar
  15. 15.
    Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al. Moderate alcohol consumption may protect against overt autoimmune hypothyroidism: a population-based case-control study. Eur J Endocrinol. 2012;167:483–90.CrossRefGoogle Scholar
  16. 16.
    Starkenburg S, Munroe ME, Waltenbaugh C. Early alteration in leukocyte populations and Th1/Th2 function in ethanol consuming mice. Alcohol Clin Exp Res. 2001;25:1221–30. Scholar
  17. 17.
    Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a high prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2004;89:6077–86.CrossRefGoogle Scholar
  18. 18.
    Laurberg P, Jørgensen T, Perrild H, Ovesen L, Knudsen N, Bulow Pedersen I, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–28.CrossRefGoogle Scholar
  19. 19.
    Tognini S, Pasqualetti G, Calsolaro V, Polini A, Monzani F. Cognitive function and quality of life in mild thyroid hormone deficiency. Recent Pat Endocr Metab Immune Drug Discov. 2014;8:124–34.CrossRefGoogle Scholar
  20. 20.
    Duntas LH, Maillis A. Hypothyroidism and depression: salient aspects of pathogenesis and management. Minerva Endocrinol. 2013;38:365–77.PubMedGoogle Scholar
  21. 21.
    Panicker V, Evans J, Bjøro T, Asvold BO, Dayan CM, Bjerkeset O. A paradoxical difference in relationship between anxiety, depression and thyroid function in subjects on and not on T4: findings from the HUNT study. Clin Endocrinol (Oxf). 2009;71:574–80.CrossRefGoogle Scholar
  22. 22.
    Dayan CM, Panicker V. Hypothyroidism and depression. Eur Thyroid J. 2013;2:168–79.CrossRefGoogle Scholar
  23. 23.
    Joffe RT, Pearce EN, Hennessey JV, Ryan JJ, Stern RA. Subclinical hypothyroidism, mood, and cognition in older adults: a review. Int J Geriatr Psychiatry. 2013;28:111–8. Scholar
  24. 24.
    Park YJ, Lee EJ, Lee YJ, Choi SH, Park JH, Lee SB. Subclinical hypothyroidism (SCH) is not associated with metabolic derangement, cognitive impairment, depression or poor quality of life in elderly subjects. Arch Gerontol Geriatr. 2010;50:e68–73.CrossRefGoogle Scholar
  25. 25.
    Chueire VB, Romaldini JH, Ward LS. Subclinical hypothyroidism increases the risk of depression in the elderly. Arch Gerontol Geriatr. 2006;44:21–8.CrossRefGoogle Scholar
  26. 26.
    Vanderpump MP, Tunbridge WM, French JM, Tunbridge F, Young ET. The development of ischemic heart disease in relation to autoimmune thyroid disease in a 20-year follow-up study of an English community. Thyroid. 1996;6:155–60.PubMedGoogle Scholar
  27. 27.
    Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham survey cohort. J Clin Endocrinol Metab. 2010;95:1734–40.CrossRefGoogle Scholar
  28. 28.
    Imaizumi M, Akahoshi M, Ichimaru S, Nakashima E, Hida A, Soda M, et al. Risk for ischemic heart disease and all-cause mortality in subclinical hypothyroidism. J Clin Endocrinol Metab. 2004;89:3365–70.CrossRefGoogle Scholar
  29. 29.
    Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467–72.CrossRefGoogle Scholar
  30. 30.
    Rodondi N, Newman AB, Vittinghoff E, de Rekeneire N, Satterfield S, Harris TB, et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch Intern Med. 2005;165:2460–6.CrossRefGoogle Scholar
  31. 31.
    Razvi S, Shakoor A, Vanderpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a meta-analysis. J Clin Endocrinol Metab. 2008;93:2998–3007. Scholar
  32. 32.
    Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frölich M, Westendorp RG. Thyroid status, disability and cognitive function, and survival in old age. JAMA. 2004;292:2591–9.CrossRefGoogle Scholar
  33. 33.
    Collet TH, Bauer DC, Cappola AR, Asvold BO, Weiler S, Vittinghoff E, et al. Thyroid antibody status, subclinical hypothyroidism, and the risk of coronary heart disease: an individual participant data analysis. J Clin Endocrinol Metab. 2014;99:3353–62. Scholar
  34. 34.
    Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131.CrossRefGoogle Scholar
  35. 35.
    Dong J, Gao C, Liu J, Cao Y, Tian L. TSH inhibits SERCA2a and the PKA/PLN pathway in rat cardiomyocytes. Oncotarget. 2016;28:39207–15. Scholar
  36. 36.
    Duntas LH, Brenta G. The effect of thyroid disorders on lipid levels and metabolism. Med Clin North Am. 2012;96:269–81. Scholar
  37. 37.
    Duntas LH, Wartofsky L. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence? Thyroid. 2007;17:1075–84.CrossRefGoogle Scholar
  38. 38.
    Cheserek MJ, Wu GR, Ntazinda A, Shi YH, Shen LY, Le GW. Association between thyroid hormones, lipids and oxidative stress markers in subclinical hypothyroidism. J Med Biochem. 2015;34:323–31. Scholar
  39. 39.
    Brenta G, Berg G, Arias P, Zago V, Schnitman M, Muzzio ML, et al. Lipoprotein alterations, hepatic lipase activity, and insulin sensitivity in subclinical hypothyroidism: response to L-T(4) treatment. Thyroid. 2007;17:453–60.CrossRefGoogle Scholar
  40. 40.
    Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab. 2012;97:326–33. Scholar
  41. 41.
    Khazan M, Amouzegar A, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Prevalence of hypothyroidism in patients with dyslipidemia: Tehran thyroid study (TTS). Horm Metab Res. 2014;46:980–4. Scholar
  42. 42.
    Maratou E, Hadjidakis DJ, Kollias A, Tsegka K, Peppa M, Alevizaki M, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009;160:785–90. Scholar
  43. 43.
    Rotondi M, Leporati P, Rizza MI, Clerici A, Groppelli G, Pallavicini C. Raised serum TSH in morbid-obese and non-obese patients: effect on the circulating lipid profile. Endocrine. 2014;45:92–7. Scholar
  44. 44.
    Asvold BO, Bjoro T, Vatten LJ. Associations of TSH levels within the reference range with future blood pressure and lipid concentrations: 11-year follow-up of the HUNT study. Eur J Endocrinol. 2013;169:73–82.CrossRefGoogle Scholar
  45. 45.
    Brenta G, Berg G, Miksztowicz V, Lopez G, Lucero D, Faingold C, et al. Atherogenic lipoproteins in subclinical hypothyroidism and their relationship with hepatic lipase activity: response to replacement treatment with levothyroxine. Thyroid. 2016;26:365–72. Scholar
  46. 46.
    Staub JJ, Althaus BU, Engler H, Ryff AS, Trabucco P, Marquardt K, et al. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues. Am J Med. 1992;92:631–42.CrossRefGoogle Scholar
  47. 47.
    Efstathiadou Z, Bitsis S, Milionis HJ, Kukuvitis A, Bairaktari ET, Elisaf MS, et al. Lipid profile in subclinical hypothyroidism: is L-thyroxine substitution beneficial? Eur J Endocrinol. 2001;145:705–10.CrossRefGoogle Scholar
  48. 48.
    Franklyn JA, Daykin J, Betteridge J, Hughes EA, Holder R, Jones SR, Sheppard MC. Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol. 1993;38:453–9.CrossRefGoogle Scholar
  49. 49.
    Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel thyroid study). J Clin Endocrinol Metab. 2001;86:4860–6.CrossRefGoogle Scholar
  50. 50.
    Danese MD, Ladenson PW, Meinert CL, Powe NR. Effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab. 2000;85:2993–3001.PubMedGoogle Scholar
  51. 51.
    Monzani F, Caraccio N, Kozàkowà M, Dardano A, Vittone F, Virdis A, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2004;89:2099–106.CrossRefGoogle Scholar
  52. 52.
    Ito M, Arishima T, Kudo T, Nishihara E, Ohye H, Kubota S, et al. Effect of levo-thyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab. 2007;92:608–11.CrossRefGoogle Scholar
  53. 53.
    Sniderman A, McQueen M, Contois J, Williams K, Furberg CD. Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol? J Clin Lipidol. 2010;4:152–5. Scholar
  54. 54.
    Michalopoulou G, Alevizaki M, Piperingos G, Mitsibounas D, Mantzos E, Adamopoulos P, et al. High serum cholesterol levels in persons with ‘high-normal’ TSH levels: should one extend the definition of subclinical hypothyroidism? Eur J Endocrinol. 1998;138:141–5.CrossRefGoogle Scholar
  55. 55.
    Duntas LH, Biondi B. New insights into subclinical hypothyroidism and cardiovascular risk. Semin Thromb Hemost. 2011;37:27–34.CrossRefGoogle Scholar
  56. 56.
    Wang G, Liu J, Yang N, Hu Y, Zhang H, Miao L, et al. Levothyroxine treatment restored the decreased circulating fibroblast growth factor 21 levels in patients with hypothyroidism. Eur J Intern Med. 2016;31:94–8. Scholar
  57. 57.
    Pearce SH, Brabant G, Duntas LH, Monzani F, Peeters RP, Razvi S, et al. 2013 ETA guideline: management of subclinical hypothyroidism. Eur Thyroid J. 2013;2:215–28. Scholar
  58. 58.
    Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, et al. American Thyroid Association Task Force on Thyroid Hormone Replacement. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24:1670–751. Scholar
  59. 59.
    Decandia F. Risk factors for cardiovascular disease in subclinical hypothyroidism. Ir J Med Sci. 2017;187(1):39–43. Scholar
  60. 60.
    Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data (IPD) analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040.CrossRefGoogle Scholar
  61. 61.
    Rodondi N, den Elzen WP, Bauer DC, Cappola AR, Razvi S, Walsh JP, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365–74.CrossRefGoogle Scholar
  62. 62.
    Biondi B. Cardiovascular effects of mild hypothyroidism. Thyroid. 2007;17:625–30.CrossRefGoogle Scholar
  63. 63.
    Cooper DS, Biondi B. Subclinical thyroid disease. Lancet. 2012;379:1142–54. Scholar
  64. 64.
    Lioudaki E, Mavroeidi NG, Mikhailidis DP, Ganotakis ES. Subclinical hypothyroidism and vascular risk: Αn update. Hormones (Athens). 2013;12:495–506. Scholar
  65. 65.
    Stott DJ, Rodondi N, Kearney PM, Ford I, Westendorp RGJ, Mooijaart SP, The TRUST Study Group, et al. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376:2534–44. Scholar
  66. 66.
    Floriani C, Gencer B, Collet TH, Rodondi N. Subclinical thyroid dysfunction and cardiovascular diseases: 2016 update. Clin Endocrinol. 2017;86:830–6. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Clinical Medicine and SurgeryUniversity of Naples Federico IINaplesItaly
  2. 2.Unit of Endocrinology Diabetes and MetabolismEvgenidion Hospital, National and Kapodistrian University of AthensAthensGreece

Personalised recommendations